Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation - Single center experience

Renal Failure

Volumn 36, Issue 9, 2014, Pages 1376-1384

  Vanikar, Aruna V ^a   Trivedi, Hargovind L ^a   Kumar, Ashutosh ^b   Gopal, Saroj Chooramani ^c   Patel, Himanshu V ^a   Gumber, Manoj R ^a   Kute, Vivek B ^a   Shah, Pankaj R ^a   Dave, Shruti D ^a  

^a Dr HL Trivedi Institute of Transplantation Sciences ITS   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c BANARAS HINDU UNIVERSITY   (India)

Author keywords

Adipose tissue derived mesenchymal stem cells; Hematopoietic stem cells; Minimization of immunosuppression; Rejection; Renal transplantation

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MEPREDNISONE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ADULT; ARTICLE; CELL COUNT; CELL VIABILITY; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INTERSTITIAL NEPHRITIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL; NONMYELOABLATIVE CONDITIONING; PORTAL VEIN BLOOD FLOW; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; ADIPOSE TISSUE; AGED; CLINICAL TRIAL; CYTOLOGY; FLOW CYTOMETRY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; AGED; AUTOANTIBODIES; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84907440929     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.950931     Document Type: Article

References (41)

1. Vanikar AV, Goplani KR, Feroz A, et al. Operational tolerance in living-related renal transplantation: A single-center experience. Transplant Proc. 2011;43(5):1551-1558.
2. Trivedi HL, Vanikar AV, Modi PR, et al. In pursuit of the ultimate: The initial Ahmedabad journey toward transplantation tolerance. Transplant Proc. 2007;39(3):653-657.
3. Vanikar AV, Trivedi HL, Feroz A, et al. Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hypo-responsiveness. Int Urol Nephrol. 2011;43(1):225-232.
4. Nakajima H, Leonard WJ. Impaired peripheral deletion of activated T cells in mice lacking the common cytokine receptor gamma chain. J Immunol. 1997;159:4737-4744.
5. Fangmann J, Dalchau AR, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med. 1992;175:1521-1529.
6. Sherwood RA, Brent L, Rayfield LS. Presentation alloantigens by host cells. Eur J Immunol. 1986;16:569-574.
7. Auchincloss Jr H. In search of the elusive Holy Grail: The mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant. 2001;1:6-12.
8. Shirwan H. Chronic allograft rejection: Do the Th 2 cells preferentially induced by indirect alloantigen recognition play a dominant role? Transplantation. 1999;68:715-726.
9. Vincenti F. Immunosuppression minimization: Current and future trends in transplant immunosuppression. J Am Soc Nephrol. 2003; 14:1940-1948.
10. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001;71:1282-1287.
11. Kreis H, Cisterne J-M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69: 1252-1260.
12. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study. Steroid Withdrawal Study Group. Transplantation. 1999;68:1865-1874.
13. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation. 2000;70:1352-1359.
14. Squifflet J-P, Vanrenterghem Y, van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: Results of a large, prospective, multicenter, randomized study. Transplant Proc. 2002;34:1584-1586.
15. Salvatierra O, Melzer J, Potter D, et al. A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation. 1985;40:654-659.
16. Terasaki PI. The beneficial transfusion effect on kidney graft survival attributed to clonal deletion. Transplantation. 1984;37: 119-125.
17. Kirk AD, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. Transplant Int. 2005;18:2-14.
18. Ricordi C, Karatzas T, Nery J, et al. High-dose bone marrow infusions to enhance allograft survival. The effect of timing. Transplantation. 1997;63(1):7-11.
19. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation. 2001;71:827-835.
20. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 2002;74:1405-1409.
21. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 2002;73:1386-1391.
22. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transplant Int. 2008;21:742-754.
23. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants - A randomized controlled trial. J Am Med Assoc. 2012;307(11):1169-1177.
24. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80:1051-1059.
25. Szczech LA, Berlin JA, Feldman HI. Anti-lymphocyte antibody induction therapy study group. The effect of antilymphocyte induction therapy on renal allograft survival. A metaanalysis of individual patient-level data. Ann Intern Med. 1998;128: 817-826.
26. Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of Thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidneypancreas transplant recipients. Transplantation. 2002;73: 1514-1518.
27. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause specific mortality in renal transplant recipients. J Am Soc Nephrol. 2002; 13:769-772.
28. Jae Woo Jung, Minsuk Kwon, Jae Chol Choi, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54(5):1293-1296.
29. Ikehara S. New strategies for allogeneic bone marrow transplantation and organ allografts. Acta Hematol. 1999;101:68-77.
30. Gorczynski RM, Chen Z, Kai Y, Lei J. Evidence for persistent expression of OX2 as a necessary component of prolonged renal allograft survival following portal vein immunization. Clin Immunol. 2000;97(1):69-78.
31. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99: 3838-3843.
32. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20.
33. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation. 2003;75:389-397.
34. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.
35. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood. 2003;101: 3722-3729.
36. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20.
37. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722-3729.
38. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B- cell functions. Blood. 2006;107:367-372.
39. Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. Adipose tissuederived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009;126:37-42.
40. Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90:1312-1320.
41. Calne RY, Friend PJ, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low dose cyclosporine monotherapy in renal allograft recipients (letter). Lancet. 1998;351:1701-1702.